

Title (en)  
COMPOSITIONS COMPRISING GLYCOSAMINOGLYCANS OF LOW VISCOSITY AND USE OF SAID COMPOSITION IN THERAPY OF CHRONIC CYSTITIS

Title (de)  
ZUSAMMENSETZUNGEN MIT GLYCOSAMINOGLYCANEN NIEDRIGER VISKOSITÄT UND VERWENDUNG DER ZUSAMMENSETZUNG BEI DER BEHANDLUNG VON CHRONISCHER CYSTITIS

Title (fr)  
COMPOSITIONS COMPRENANT DES GLYCOSAMINOGLYCANES DE FAIBLE VISCOSITÉ ET UTILISATION DE LADITE COMPOSITION DANS LE TRAITEMENT DE LA CYSTITE CHRONIQUE

Publication  
**EP 2034956 B2 20230628 (EN)**

Application  
**EP 07729534 A 20070525**

Priority  

- EP 2007055107 W 20070525
- IT MI20061030 A 20060526

Abstract (en)  
[origin: WO2007138014A1] The present invention concerns new compositions comprising glycosaminoglycans, intended for use in interstitial cystitis therapy, and characterized by a controlled viscosity.

IPC 8 full level  
**A61K 9/08** (2006.01); **A61K 31/728** (2006.01); **A61K 31/737** (2006.01)

CPC (source: EP US)  
**A61K 9/0019** (2013.01 - EP US); **A61K 9/0034** (2013.01 - EP US); **A61P 1/16** (2017.12 - EP); **A61P 13/10** (2017.12 - EP)

Citation (opposition)  
Opponent :  

- WO 2004034980 A2 20040429 - MARCUM FRANK D [US]
- WO 03034993 A2 20030501 - PETITO GEORGE D [US], et al
- EP 0136782 A2 19850410 - CILCO INC [US]
- EP 0136782 B1 19920318
- US 2004082540 A1 20040429 - HERMIDA OCHOA ELIAS HUMBERTO [MX]
- EP 0971694 B1 20040526 - LAM PHARMACEUTICAL CORP [US]
- US 5627162 A 19970506 - GWON ARLENE E [US], et al
- US 6780841 B2 20040824 - ISHAQ SUHAIL [US]
- US 5498606 A 19960312 - SOLL DAVID B [US], et al
- WO 2006035969 A1 20060406 - SENJU PHARMA CO [JP], et al
- CA 2269260 A1 20001016 - STELLAR INTERNAT INC [CA]
- EP 1124546 B1 20040421 - BIONICHE LIFE SCIENCES INC [CA]
- EP 1365777 B1 20060419 - THEOHARIDES THEOHARIS C [US]
- US 6083933 A 20000704 - HAHN SUNGTACK SAMUEL [CA]
- WO 0209728 A1 20020207 - DERMAL RES LAB INC [US], et al
- US 4486416 A 19841204 - SOLL DAVID B [US], et al
- GARG ET AL.: "Chemistry and Biology of Hyaluronan", 2004, ELSEVIER, article TIM HARDINGHAM: "Chapter 1 Solution Properties of Hyaluronan", pages: 1 - 19
- SCOTT E.J.: "Structure and function in extracellular matrices depend on interaction between anionic glycosaminoglycans", PATHOL. BIOL., vol. 49, 2001, pages 284 - 289
- SCOTT E.J.: "Hyaluronan forms specific stable tertiary structures in aqueous solution A 13C NMR study", PROC. NATL. ACAD. SCI. USA, vol. 96, no. 9, 27 April 1999 (1999-04-27), pages 4850 - 4855
- "Hyaluronsäure", WIKIPEDIA, 2 December 2018 (2018-12-02), pages 1 - 7
- "Chondroitin", WIKIPEDIA, 24 June 2018 (2018-06-24), pages 1 - 6
- "Viskosität", WIKIPEDIA-EXZERPT, 11 December 2018 (2018-12-11), pages 9
- "Viskosimeter", WIKIPEDIA, 8 August 2018 (2018-08-08), pages 1 - 6
- "Val (Einheit)", WIKIPEDIA, pages 1 - 3
- "Interstitielle Zystitis", WIKIPEDIA, 8 May 2015 (2015-05-08), pages 1 - 2
- "Interstitial cystitis", WIKIPEDIA, 12 May 2015 (2015-05-12), pages 1 - 13
- SAUL J. FARBER ET AL.: "The Binding of Cations by Chondroitin Sulfate", J. CLIN. INVEST., vol. 36, no. 12, 1957, pages 1715 - 1722
- MARY A. NAPIER ET AL.: "Effect of calcium on structure and function of a hyaluronic acid matrix: Carbon-13 nuclear magnetic resonance analysis and the diffusional behavior of small solutes", PROC. NATL. ACAD. SCI. USA, vol. 75, no. 5, May 1978 (1978-05-01), pages 2261 - 2265
- JULIA EINBINDER ET AL.: "Crystallization of Calcium Chondroitin Sulfate", J. BIOL. CHEM., vol. 191, 1951, pages 591 - 597
- SABURO SHIMABAYASHI ET AL.: "Interaction of Hydroxyapatite with Sodium Chondroitin Sulfate and Calcium Chondroitin Sulfate in an Aqueous Phase", CHEM. PHARM. BULL., vol. 37, no. 6, June 1989 (1989-06-01), pages 1437 - 1440
- PAUL J. HAUSER ET AL.: "Restoration of the Barrier Function to Acid-Damaged Bladder by Intravesical Chondroitin Sulfate", NIH PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 2, no. 5, 18 November 2009 (2009-11-18), pages 1 - 14
- ROBERT E. HURST ET AL.: "Functional and structural characteristics of the glycosa- minoglycans of the bladder luminal surface", PUBMED, vol. 138, no. 2, August 1987 (1987-08-01), pages 1
- ROBERT E. HURST ET AL.: "Functional and structural characteristics of the glycosa- minoglycans of the bladder luminal surface", THE JOURNAL OF UROLOGY, vol. 138, no. 2, August 1987 (1987-08-01), pages 433 - 437
- G. STEINHOFF: "The Efficacy of Chondroitin Sulphate in Treating Interstitial Cystitis", EUROPEAN UROLOGY SUPPLEMENTS, vol. 2, 2003, pages 14 - 16
- "Bladder Disease: Research Concepts and Clinical Applications", 2003, article G. STEINHOFF ET AL.: "Chapter 45 The Efficacy of Intravesicular Sterile Sodium Chondroitin Sulfate 0,2% in Potassium Tested Positive Patients with Interstitial Cystitis", pages: 731 - 739
- R E HURST: "Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract", WORLD J. UROL., vol. 12, 1994, pages 3 - 10
- ROBERT E. HURST ET AL.: "A Deficit of Chondroitin Sulfate Proteoglycans on the Bladder Uroepithelium in Interstitial Cystitis", UROLOGY, vol. 48, no. 5, 1996, pages 817 - 821

- R. PEEKER ET AL.: "Treatment Guidelines for Classic and Non-Ulcer Interstitial Cystitis", INT. UROGYNECOL. J., vol. 11, 2000, pages 23 - 32
- E. CONSTANTINI ET AL.: "Morphological Changes of Bladder Mucosa in Patients Who Underwent Instillation with Combined Sodium Hyaluronic Acid-Chondroitin Sulfate (Ialuri®)", UROL. INT., vol. 91, 2013, pages 81 - 88
- FRANCE SCA MACCARI ET AL.: "Fine structural characterization of chondroitin sulfate in urine of bladder pain syndrome subjects", INT. UROGYNECOL. J., vol. 22, 2011, pages 1581 - 1586
- J.K. SHEEHAN ET AL.: "Effect of the cations sodium, potassium and calcium on the interaction of hyaluronate chains: a light scattering and viscometric study", INT. J. BIOL. MACROMOL., vol. 5, 1983, pages 222 - 228
- Polymer Science Learning Center, "How Polymers Work Meaning of Molecular Weight" (cited 10.05.2019)
- Declaration Dr. Nadia Puppin, 15. May 2019
- Volpi, Nicola, "Analytical Aspects of Pharmaceutical Grade Chondroitin Sulfates" Journal of Pharmaceutical Sciences, Vol. 96, No. 12, 12. December 2007
- EDOM - COUNCIL OF EUROPE, "European Pharmacopoeia - Chondroitin Sulfate Sodium", 2017
- Wikipedia-Exzerpt "Molmassenverteilung", 6 Seiten
- Internet-Exzerpt gemäss <https://www.thoughtco.com/definition-of-molecularweight-605369>. 6 Seiten
- Internet-Exzerpt gemäss [https://www.acronymfinder.com/Molecular-Weight-\(MW\).html](https://www.acronymfinder.com/Molecular-Weight-(MW).html)
- Internet-Exzerpt gemäss <https://www.ilpi.com/msds/ref/mole.html>
- J.B. Park und R.S. Lakes, "Biomaterials - An Introduction", Second Edition, Springer Science + Business Media. LLC.1992, Seiten 190 bis 192
- Äquivalent-Berechnungen zu den Streitpatent gemässen Ausführungsbeispielen
- Äquivalent-Berechnungen zu den nachgereichten Versuchen der Patentinhaberin gemäss Dokument D39
- Äquivalent-Beispielrechnung zu Ausführungsbeispiel 12
- Replica of D48 with different calculation method
- Page 21 of Opponent submission with annotations

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

**WO 2007138014 A1 20071206**; CA 2653369 A1 20071206; CA 2653369 C 20151117; DK 2034956 T3 20180522; DK 2034956 T4 20230724; EP 2034956 A1 20090318; EP 2034956 B1 20180321; EP 2034956 B2 20230628; ES 2664951 T3 20180424; ES 2664951 T5 20230927; FI 2034956 T4 20230831; HU E037542 T2 20180928; IT MI20061030 A1 20071127; JP 2009538287 A 20091105; JP 5177446 B2 20130403; PL 2034956 T3 20180831; PL 2034956 T5 20230807; TR 201808687 T4 20180723; US 2009181924 A1 20090716; US 8252770 B2 20120828

DOCDB simple family (application)

**EP 2007055107 W 20070525**; CA 2653369 A 20070525; DK 07729534 T 20070525; EP 07729534 A 20070525; ES 07729534 T 20070525; FI 07729534 T 20070525; HU E07729534 A 20070525; IT MI20061030 A 20060526; JP 2009511530 A 20070525; PL 07729534 T 20070525; TR 201808687 T 20070525; US 22776107 A 20070525